Printer Friendly

Nordic Nanovector announces promising results from preclinical research collaboration to develop novel CD37-targeting alpha therapy for B-cell tumours.

M2 EQUITYBITES-April 2, 2019-Nordic Nanovector announces promising results from preclinical research collaboration to develop novel CD37-targeting alpha therapy for B-cell tumours

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Nordic Nanovector ASA (OSE: NANO), a developer of targeted therapies for haematological cancers, reported on Tuesday that the results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours are promising.

The company said that in June 2016, it established the research collaboration with Orano Med (formerly known as AREVA Med) to develop and investigate a next-generation targeted alpha therapy. This therapy is comprised of Nordic Nanovector's chimeric anti-CD37 antibody (NNV003) and the alpha-particle-generator lead-212 (212Pb) for the treatment of B-cell malignancies.

According to Nordic Nanovector, results from the research describe promising findings from preclinical studies investigating the tolerability and dose-dependent efficacy of 212Pb-NNV003 in mouse models of chronic lymphocytic leukaemia (CLL) and Burkitt's lymphoma (a type of non-Hodgkin's lymphoma, NHL).

These studies found that 212Pb-NNV003 displayed a favourable toxicity profile after a single intravenous injection. In one study, 100% of mice with tumour xenografts were alive five months after the injection of 212Pb-NNV003, while only 50% of control mice receiving cold antibody where alive after 1.5 months.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Financial report
Date:Apr 2, 2019
Words:214
Previous Article:Luxfer announces dividend of USD0.1205 per ordinary share.
Next Article:Audi UK adds new TT RS to range.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters